Invigorating microbiome-centric therapeutics to save lives!
Beyond the limits of human intelligence!
Our Story
Commitment to Patients
Natalia Kirsten, MD
Dermatologist, K-LABS HC Ltd.
"I was born into a family of doctors. From early childhood, I spent a lot of time after school in the hospital or in the laboratory next to my parents. During this time, I learned not only about medicine itself, but about the vast soothing impact it has on the lives of those who suffer. Being a doctor became my identity. But in my work with patients, I repeatedly saw the limits of approved therapies and thus of my work as a doctor. At the same time, some of the solutions were so obvious to me. So, I made it my mission to dedicate myself to the development of novel therapeutic approaches and to implement these innovative concepts not only in medical indications, but also in the daily care of the skin and the body."
A Partnership is Born
Mr. Ronald Shannon, Epidemiologist, Health Economist,
Microbiome Entrepreneur
Dr. Kirsten met Mr. Shannon in Hamburg, Germany in 2018, where he was collaborating with research and public health projects. At the same time he revealed his successful abilities as an entrepreneur and global knowledge to develop solutions that are effective, safe, and sustainable. His solutions have facilitated several medical and microbiome commercial products and exit. A partnership was born. Innovative microbiome-related products are established for health and cosmetics. Three companies are now established and growing for microbiome consumer products and therapeutics in human and animals.
A Passion to Innovate & Save Lives
We are committed to innovation and constantly pushing the boundaries of what is possible in biotechnology and artificial intelligence, developing new and groundbreaking solutions that address some of the world's most pressing healthcare challenges of our time.
Our Pipeline to Success
Strain Selection
We work with new and well selected probiotic strains to identify best candidates for further evaluation and processing to develop new microbiome based therapeutics. The selected novel strains undergoe inactivation and predictive testing with latest biotechnology and deep learning methods to determine safety, effectiveness and cost benefit to humans and animals.
Precision Inactivation
The idea behind using non-viable microbes is to remove the many drawbacks associated with the administration of viable microorganisms. Scientific evidence has demonstrated that the biogenic functions of inactivated cells of microbes, microbial fractions, or cell lysates could sustain human as well as animal health. The inactivating method is critical to correctly producing and interpreting these results. Our portfolio of novel methods is building to inactivate with precision and cost-effectiveness.
Predictive Testing
The most advanced methods are used to predict clinical effectiveness including validated organ-on-chip technology and artificial intelligence. We always utilize molecular, microbiology, and omics tools to quantify our external and internal cell structures and related biochemical endpoints before and after inactivation.
Deep Learning
Deep and machine learning, a segment of artificial intelligence, is paving the way for innovation in the biological sciences. We aspire to collect Big-Nano microbiome data from our internal and external data systems and create innovative algorithms to predict human and non-human health outcomes. This will save time, money and lives!
Our Partners
